Orthocell Ltd (ASX:OCC) has received a new US divisional patent for CelGro® that covers the method of manufacture of collagen medical devices and as an aid in the surgical repair of soft tissue injuries.
The patents entitled ‘Method for Producing a Collagen Membrane and Uses Thereof’ provides additional important intellectual property (IP) to protect the CelGro® platform for soft tissue regeneration and repair applications and expires in June 2033.
Orthocell has already been granted patents for CelGro® in the US, Canada, Europe, China, Japan, Singapore, Australia and New Zealand with CelGro® dental (recently renamed Striate+) approved for use in the US, Europe and Australia.
According to the company, the global addressable market for CelGro® is more than US$10 billion and is growing.
“Strengthens IP position”
Orthocell managing director Paul Anderson, said: “This is an important patent that further protects and strengthens our IP position for CelGro® providing greater layers of protection.
“This patent also complements the recent market approval of the first CelGro® product, Striate+ for dental bone and soft tissue repair procedures approved in the US, EU and Australia.”
Patents covering portfolio
Orthocell has secured 11 patent families covering its portfolio of breakthrough regenerative medicine products, comprising 110 separate patents applications out of which 75 are already granted.
CelGro® is a customisable collagen medical device manufactured by the company at its GMP certified facility in Western Australia, using its proprietary SMRTTM tissue engineering process.
The company believes CelGro® has numerous competitive advantages over existing synthetic and biologic tissue repair devices, particularly in the areas of cell biocompatibility, tensile strength and the promotion of high-quality tissue repair.
Use of CelGro® has shown to result in high-quality outcomes in the repair of bone defects in the jaw, assist in the re-joining of severed or damaged peripheral nerves and augment repair of the rotator cuff tendon within the shoulder.
Striate+
CelGro® dental, which has recently renamed Striate+, has already been approved for use in the US, Europe and Australia
Striate+ is the first product from the CelGro® platform technology to gain US, EU and Australian approval.
It has distinct advantages over other similar products and may assist surgeons to deliver improved patient outcomes through superior handling characteristics, tissue integration qualities and improved bone healing.
With major market approvals achieved and key opinion leaders actively engaging with the program, Orthocell is well-positioned to secure a distribution partner and establish Striate+ as the best-in-class dental resorbable collagen membrane.